First Patient Dosed in Ph 1a Trial of QN-302 in Advanced or Metastatic Solid Tumors December 11, 2023
FDA granted “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic EDV (EnGeneIC Dream Vector) December 11, 2023
Ph 3 CheckMate -8HW Trial of Opdivo + Yervoy vs Chemo in MSI-H or MRD Metastatic CRC Meets Primary endpoint December 11, 2023
Imfinzi + Avastin met primary endpoint for PFS in liver cancer eligible for embolisation in EMERALD-1 Ph 3 trial December 4, 2023
Positive EU CHMP Opinion for KEYTRUDA Plus Gemcitabine and Cisplatin as 1L Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer December 4, 2023
2nd Independent Safety Review of the ASPIRE Registration Clinical Trial Announced: Recommended Continuation with no Trial Modification December 4, 2023
Subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types December 4, 2023
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer November 29, 2023
FDA Approves KEYTRUDA + Chemotherapy as 1L Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or GEJ Adenocarcinoma November 29, 2023
FDA Approves KEYTRUDA + Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer November 7, 2023
Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for Camrelizumab + Rivoceranib for uHCC October 25, 2023
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA October 25, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study Released October 25, 2023
Clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab to be discontinued October 18, 2023
New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized 1L HCC Study presented October 16, 2023
Interim Results from Ph 2 Trial of IT LSAM-PTX in Locally Advanced Pancreatic Cancer Patients Announced October 16, 2023
Positive EU CHMP Opinion for KEYTRUDA + Chemo as 1L Treatment for HER2-Negative Advanced GEJ Adenocarcinoma Expressing PD-L1 (CPS ≥1) October 16, 2023
Positive Interim Ph 2 ASPEN-06 Trial Results of Evorpacept in Advanced HER2+ve Gastric Cancer Reported October 11, 2023
